Corcept Therapeutics Ends Late Stage Trial of Mifepriston; Groupon Projects Weak Guidance for Current Quarter

Follow this company

Companies Mentioned

05/08/2014 [ACCESSWIRE]

AOL Inc. (NYSE: AOL) - For an in-depth report on AOL Inc. follow:

Shares of AOL Inc. closed down 20.62% on nearly 14 million shares traded on Wednesday. The company reported first quarter earnings that came in below analysts' estimates. In Q1 net income declined 64% from a year ago to $9.3 million. Total quarterly revenue grew 8% to $583.3 million. Adjusted earnings per share of 34 cents trailed analysts' estimate of 45 cents, according to Thomson Reuters.

Groupon, Inc. (NASDAQ: GRPN) - For an in-depth report on Groupon, Inc. follow:

Groupon shares dropped 20.68% on Wednesday with 71.3 million shares traded. The company was a big decliner on the NASDAQ and even hit a new yearly low of $5.18 during intra-day trading.  The company posted weak guidance in its first-quarter earnings report. For the current quarter, Groupon has projected earnings of just breakeven to $0.02 a share, below estimates of $0.03.

IDS Industries, Inc. (OTCBB: IDST) - For an in-depth report on IDS Industries, Inc. follow:

Shares of IDS Industries closed up 30.77% on Wednesday with about 5.3 million shares traded. The stock was a big winner in the OTCBB market. The company announced that their wholly-owned subsidiary, Charge! Energy Storage, Inc. has entered into a contract manufacturing and marketing agreement with Ultralife Corporation for the Charge! Energy branded line of portable and stationary power systems.

Corcept Therapeutics Incorporated (NASDAQ: CORT) - For an in-depth report on Corcept Therapeutics Incorporated follow:

Shares of Corcept Therapeutics Incorporated closed down 50.50% on Wednesday with about 4.6 million shares traded. The stock was one of the biggest decliners on the NASDAQ after the company announced that they would end a late-stage trial of its depression treatment drug Mifepriston. Data analysis from the first 226 patients enrolled in the trial determined the drug did not significantly reduce psychotic depression symptoms.


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.


Leave a comment...

Your Name